Clinical Trials
6 trialsNCT02538432 2019-11-04
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
University of Maryland, Baltimore
Phase 2 Withdrawn
NCT02944357 2017-11-17
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Mayo Clinic
Phase NA Withdrawn
NCT01639521 2014-01-29
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
University of Southern California
Phase 2 Withdrawn
NCT00014287 2013-12-19
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
University of Pittsburgh
Phase 1 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT00696007 2012-02-17
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
Lahey Clinic
Phase 2 Withdrawn